While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Luckily for you, we built StockStory to help you separate the good from the bad. That said, here is one cash-producing company that reinvests wisely to drive long-term success and two that may face some trouble.
Two Stocks to Sell:
Vontier (VNT)
Trailing 12-Month Free Cash Flow Margin: 12.1%
A spin-off of a spin-off, Vontier (NYSE:VNT) provides electronic products and systems to the transportation, automotive, and manufacturing sectors.
Why Do We Steer Clear of VNT?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Projected sales decline of 2.1% for the next 12 months points to an even tougher demand environment ahead
- Earnings per share lagged its peers over the last five years as they only grew by 1.2% annually
At $30.16 per share, Vontier trades at 8.7x forward P/E. Read our free research report to see why you should think twice about including VNT in your portfolio.
Excelerate Energy (EE)
Trailing 12-Month Free Cash Flow Margin: 16.4%
Operating specialized vessels that can deliver up to 1.2 billion cubic feet of natural gas per day, Excelerate Energy (NYSE:EE) provides liquified natural gas regasification services using floating vessels that convert LNG back into natural gas.
Why Are We Wary of EE?
- Revenue base of $1.35 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Gross margin of 29.5% reflects its high production costs and unfavorable asset base
Excelerate Energy’s stock price of $39.68 implies a valuation ratio of 25.3x forward P/E. Check out our free in-depth research report to learn more about why EE doesn’t pass our bar.
One Stock to Watch:
Halozyme Therapeutics (HALO)
Trailing 12-Month Free Cash Flow Margin: 44.3%
Known for transforming hours-long intravenous infusions into minutes-long subcutaneous injections, Halozyme Therapeutics (NASDAQ:HALO) develops and licenses its proprietary ENHANZE technology that enables subcutaneous delivery of injectable drugs that would otherwise require intravenous administration.
Why Are We Fans of HALO?
- Market share has increased this cycle as its 32.2% annual revenue growth over the last two years was exceptional
- Earnings per share have massively outperformed its peers over the last five years, increasing by 28.7% annually
- HALO is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders
Halozyme Therapeutics is trading at $80.60 per share, or 8.9x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.